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The Selenium and Vitamin E Cancer Prevention Trial (SELECT)
was one of the largest human cancer prevention trials ever undertaken. Designed to examine the role of selenium and vitamin E in
preventing prostate cancer (1) as a double-blind study, SELECT
administered daily 200 micrograms of selenium in the form of
pure L-seleilomethionine,400 1IJ of synthetic D,L-a-tocopherol
(vitamin E), a combination of these two components, or a placebo
to four approximately equally divided groups. SELECT enrollinent
was undertaken between A~tgust22,2001 and June 24, 2004, and
involved 35.533 healthy males from more than 425 participating locations in the United States, Puerto Rico, and Canada. The
baseline ages of males selected were fifty years or older for African
Americans, and fifty-five years or older for all others. No significant differences in prostate cancer incidence were observed in
any of the groups; hou~ever,slight but statistically non-significant
incieases were observed in prostate cancer risk within the vitamin E group and in type 2 diabetes mellitus within the selenium
group. Therefore, although SELECT was planned to include a
twelve year intervention period, intervention was discontinued
after a median period of 5.46 years (2).
SELECT clearly establishes that selenium in the form of
L-selenomethionine,when administered to the diet of healthy
American males fifty years of age and older, does not prevent
prostate cancer. This important observation raises questions as
to why SELECT'Sfindings are different from those of earlier trials (3-8) and numerous animal studies (9, 10) that also employed
selenium, but showed dramatic reductions in certain forms of
cancer. For ex?mple, the Nu~ritionalPrevention of Cancer (NPC)
trial was undertaken to examine the role of selenium in preventing skin cancer (5-7). Each patient taking part in the study had
a prior incidence of skin basal and/or squainous cell carcinoma.
Even though the NPC trial did not decrease skin cancer incidence
(61, it found dramatic reductions in other fonns of cancer, as well
as in cancer mortality NPC initially reported that prostate cancers
were reduced 63%, colorectal cancers 58%, and lung cancers 48%
(5). A subsequent analysis of the complete NPC trial data reported
that selenium supplementation reduced total and prostate cancer
incidence but did not reduce lung or colorectal cancer incidence
significantly (6). In addition, NPC had two limitations: it involved
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Figure 1. Selenomethlonlne metabolism In mammals. Major metabolites of
selenomethionine are shown. The incorporation of selenocysteine into protein
by replacing cysteine is proposed by analogy to other organisms but has not
been verified in humans. For further reading on selenomethionine metabolism
see (23, 24).

a relatively small number of subjects (1,312) and was initially
planned to examine the role of selenium in skin cancer prevention,
thus considering risk factors only for that endpoint in randomizing
subjects. In spite of these factors, the NPC trial, along with the
other studies noted above, provided the impetus for undertaking
the much larger SELECT. Other trials (also noted above) employing vitamin E provided the basis for using this vitamin in SELECT
(3, 4, 8). An exciting anticipation for SELECT was the elucidation
of many other possible roles of selenium and vitamin E in initigating other cancer forms and or other diseases such as their roles in
preventing cardiovascular disease.
To understand what SELECT tells us about the role of selenium in cancer prevention, one should exanline differences and
similarities between SELECT and the earlier clinical trials and take
into consideration results from many laboratory animal studies,
almost all of which have shown protective effects of selenium.
Although the SELECT investigators addressed some of these questions and possible reasons for the discrepancies, further analysis is
appropriate. We see SELECT as differing from other clinical trials
of selenium in two ways: it used a different foml of selenium, and
it used subjects of higher selenium status. Because of our expertise
in selenium rather than in vitamin E, this commentary focuses
mainly on the role of selenium in cancer.
SELECT used pure L-selenomethionine as the intervention
agent (1, 2), whereas other human trials and animal studies have
demonstrated anti-tumorigenic efficacy for selenite and seleniumenriched baker's yeast. Although L-selenomethioninerepresents
the major form of selenium in high-selenium yeast, that product
has been shown to include other chemical forms of selenium (1 1).
Selenonlethionine provides selenium for selenoprotein biosynthe-
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any of the groups; however, slight but statistically non-significant
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group. Therefore, although SELECT was planned to include a
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after a median period of 5.46 years (2).
SELECT clearly establishes that selenium in the form of
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a prior incidence of skin basal and/or squamous cell carcinoma.
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a relatively small number of sul~jects(1,312) and was initially
planned to examine the role of selenium in skin cancer prevention,
thus considering risk factors only for that endpoint in randomizing
subjects. In spite of these factors, the NPC trial, along with the
other studies noted above, provided the impetus for undertaking
the much larger SELECT. Other trials (also noted above) employing vitamin E provided the basis for using this vitamin in SELECT
(3, 4, 8). An exciting anticipation for SELECT was the elucidation
of many other possible roles of selenium and vitamin E in mitigating other cancer forms and or other diseases such as their roles in
preventing cardiovascular disease.
To understand what SELECT tells us about the role of selenium in cancer prevention, one should examine differences and
similarities between SELECT and the earlier clinical trials and take
into consideration results from many laboratory animal studies,
almost all of which have shown protective effects of selenium.
Although the SELECT investigators addressed some of these questions and possible reasons for the discrepancies, further analysis is
appropriate. We see SELECT as differing from other clinical trials
of selenium in two ways: it used a different form of selenium. and
it used subjects of higher selenium status. Because of our expertise
in selenium rather than in vitamin E, this commentary focuses
mainly on the role of selenium in cancer.
SELECT used pure L-selenomethionine as the intervention
agent (1,2), whereas other human trials and animal studies have
demonstrated anti-tumorigenic efficacy for selenite and seleniumenriched baker's yeast. Although L-selenomethionine represents
the major form of selenium in high-selenium yeast, that product
has been shown to include other chemical forms of selenium (I 1).
Selenomethionine provides selenium for selenoprotein biosynthe-

After All." We consider the
widespread use of blanket
statements regarding the null
SELECT results to miss both
the discrepancy noted above
and the question raised by that
discrepancy: that is, who can
benefit from selenium supplementation? However, SET-ECT,
when compared to other findings showing selenium as a
cancer chemopreventivr agent.
has taught us a great deal, and
its results should both modify
our understanding of the role
of this element in cancer
and suggest better strategies
for targeting selenium to the
human population.
For the most part, human
clinical trials have been undertaken with little understanding
about how
acts
Figure 2. One outcome of SELECT Is the need for baslc studies to understand selenium biology. Three basic
approaches are illustrated in the figure by a nucleotide sequence highlighting the need for additional human genetics
at the molecular level and
and polymorphism analyses, a mouse for the use of animal models and a protein structure for the functional analyses
the overall potential
of selenoproteins.
consequences of administering
sis via the transsulfuration pathway, but it can be diverted from
this nutritional micronutrient to such a large number of individuthat pathway into general protein synthesis-in lieu of its sulfurals. Recent studies have shown that some selenium-containing
analog, methionine-and it can be used in a number of other ways proteins (selenoproteins), such as thioredoxin reductase 1 (TRl),
(Figure 1).This differentiatesselenomethionine from other selemay have roles in preventing cancer, but once the malignancy is
nium compounds, which cannot be so diverted and, therefore, are
initiated, TR1 may actually contribute to progression of the disease
[see (14) and references therein]. Other studies in mice have shown
methylated to lorn1 methylselenol, a presuinptive antitumorigenic
that selenium deficiency may inhibit some forms of cancer (15, 16).
metabolite methylselenol (12).
Numerous studies involtlng human selenoproteins have shown
The subjects enrolled in SELECT had higher initial plasma
levels of selenium than those in the &PC trial (135 ng/ml and 113 a direct correlation between one of the polymorphic forms and
cancer risk (1 7-20). These studies suggest the need to learn more
ng/ml, respectively). The subjects in the NPC trial were selected,
in part, on the basis of their having relatively low serum seleniun~ about the biology of selenium before administering thls element to
levels (5);it was in this cohort that seleniunl supplementation was humans in such large numbers involving clinical trials (Figure 2).
Furthermore, another factor to consider is the costs involved that
effective in reducing cancer risks. Moreover, recent analyses show
are only a fraction in animal studies of what they are in human
that the treatment effect in the NPC trial was restricted to those
clinical trials.
with lower baseline plasma selenium concentrations (6, 7). It is of
Clearly, our understanding of selenium biology is, at the very
interest to note that the serum selenium levels of individuals in
most European countries, even those supplemented with selenium, least, incomplete. Only recently have we learned the mechanism
of selenocysteine biosynthesis in humans (21) and identified the
are lower than in unsupplemented Americans (1.3). If selenium
human set of selenoprotein genes (22). Functions of at least half
supplementation can reduce cancer risk in low-selenium subjects,
of these gene products are not known and the mechanism of
then Europe would have been a better place to conduct a cancer
the differentialregulation of various selenoproteins with varylng
prevention trial at the SELECT scale.
selenium
in the diet is still unresolved. Although much progress
The termination of the active intervention phase of SELECT
has
been
made
recently in understanding the role of polymorphic
was widely featured in on-line and printed media, including wellsites in selenoprotein genes, further studies are needed. A better
regarded newspapers such as The New York Timn, The Washington
understanding of selenium biology requires additional mechanisPost, and USA Today. The American Association of Retired Persons
tic, genetic and other experimental approaches, which should be
published a short report titled "Selenium, Vitamin E Don't Help
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informative in designing clinical studies for elucidating specific
roles of selenium in human biology
-, Then, supplementation with
selenium could be targeted to a subset of the human population.
or even to individ~~als
of a certain genotype, disease state or selenium status, that can benefit lnost from this micronutrient.
doi:10.1124/mi.9.1.6
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